Last reviewed 2026-05-24 · How we verify

Tebacon (THEBACON)

Phase 2 active Small molecule ✓ Verified May 2026

Tebacon (generic name: THEBACON) is a thebacon drug. It is currently in Phase 2 development.

Tebacon works by interacting with specific biological targets to produce a therapeutic effect.

Tebacon is a small molecule with the synonyms ACETYLDEMETHYLDIHYDROTHEBAINE, ACETYLDIHYDROCODEINONE, DEA NO. 9315, DIHYDROCODEINONE ENOL ACETATE, IDS-NT-001, and NSC-117860.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	THEBACON
Drug class	thebacon
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Tebacon is a key that fits into those locks. When Tebacon binds to its target, it helps to regulate the activity of the cells, which can lead to various therapeutic effects. This process is a complex interplay of molecular interactions that ultimately influence the body's response to the drug.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tebacon CI brief — competitive landscape report
Tebacon updates RSS · CI watch RSS

Frequently asked questions about Tebacon

What is Tebacon?

Tebacon (THEBACON) is a thebacon drug.

How does Tebacon work?

Tebacon works by interacting with specific biological targets to produce a therapeutic effect.

What is the generic name of Tebacon?

THEBACON is the generic (nonproprietary) name of Tebacon.

What drug class is Tebacon in?

Tebacon belongs to the thebacon class. See all thebacon drugs at /class/thebacon.

What development phase is Tebacon in?

Tebacon is in Phase 2.

Drug class: All thebacon drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing